News Archives - neuroCare

One moment please...

Online Referral FormsMake a referral today 1300 149 300[email protected]

Call 1300 149 300
or write to us

neuroCare Group

March 23, 2020

neuroCare Group

July 21, 2019

Medical Practitioners, Researchers and Mental Health Professionals in Melbourne are invited to join a Q&A session in August with Dr Martijn Arns, leading researcher in the areas of TMS in Depression, OCD and Neurofeedback in ADHD and Sleep Disorders.

neuroCare Group

May 1, 2019

neuroCare's Susanne Mechtersheimer will take part in the UNSW's Learning Difference Convention, detailed the HOP (homework, Organisation and Planning Skills) Program

The Conversation

September 26, 2018

A study at the University of Southern California has investigated the link between digital media use and the development of ADHD-related behaviours among 15- and 16-year-olds. This study highlights a potential association between digital media and behavioural symptoms typically associated with ADHD.

neuroCare Group

September 18, 2018

neuroCare has established a global network of clinics and training centres, now in Australia, for professionals interested in EEG Biofeedback and Neurostimulation techniques, proven to have beneficial and sustainable effects in mental health.

neuroCare Group

July 1, 2018

New study shows brain activity measured by QEEG can help predict which children may or may not respond to medications for ADHD

neuroCare Group

February 19, 2018

Researchers compare methods of treating ADHD in children and find that Neurofeedback, a medication-free technique, has long-lasting effects, according to a recent study published in the medical journal European Child & Adolescent Psychiatry.

neuroCare Group

February 6, 2018

Researchers find cost of rTMS treatment to be more cost-effective as compared to antidepressant medication trials, factoring in financial commitment and quality of life post treatment.

neuroCare Group

November 15, 2017

New study shows that magnetic brain stimulation (TMS) combined with concurrent psychotherapy is more effective than either technique alone with 66% of research subjects with Depression responding well in an average of 21 session. 65% of the group achieved long-term benefit.

neuroCare Group

October 26, 2017

Members of the Royal Australian and New Zealand College of Psychiatry are putting forward a new submission to have TMS subsidized under Australia’s public health fund, Medicare.

Older Posts

Logo neuroCare bunt Poster vector white 1

neuroCare is innovating mental health and performance by personalising therapy following a detailed assessment. neuroCare’s objective, measurable and effective approach is based on our natural ability to learn (neuroplasticity) and technology to accelerate the learning (neuromodulation).

To learn more about what we do worldwide
www.neurocaregroup.com

neuroCademy Professional Training & Science
www.neurocademy.com

Search

Digital Agency - Supple

Call now

A Message To Our Clients Regarding Coronavirus

Dr Martijn Arns visits Melbourne for talk series “Neuromodulation in Australia: New Approaches in Mental Healthcare”

Find out more about the HOPS Program at the Learning Difference Convention, Sydney

Research Check: are phone-obsessed teens at greater risk of ADHD?

Professional Neuromodulation Training in Sydney – New Workshops Announced for 2019

Brain activity predicts response to medication in ADHD

New Study Confirms Neurofeedback has long-term benefit for Children with ADHD

TMS more cost-effective treatment for major depressive disorder, study finds

Combined TMS and Psychotherapy more effective treatment for Depression

Australian Psychiatrists push for TMS to be subsidised

Search